AVEO Oncology Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
115
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$566M
AVEO Oncology General Information
Description
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Contact Information
Website
www.aveooncology.com(Operating Subsidiary)
Corporate Office
- One Marina Park Drive
- 12th Floor
- Boston, MA 02210
- United States
Corporate Office
- One Marina Park Drive
- 12th Floor
- Boston, MA 02210
- United States
AVEO Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Merger/Acquisition | 19-Jan-2023 | $566M | Completed | Generating Revenue | ||
| 16. 2PO | 16-Aug-2018 | Completed | Generating Revenue | |||
| 15. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 14. 2PO | 29-Mar-2017 | Completed | Profitable | |||
| 13. PIPE | 13-May-2016 | Completed | Profitable | |||
| 12. Secondary Transaction - Open Market | 14-Feb-2014 | Completed | Profitable | |||
| 11. Secondary Transaction - Open Market | 01-Jan-2014 | Completed | Profitable | |||
| 10. PIPE | 31-Dec-2013 | Completed | Profitable | |||
| 9. Secondary Transaction - Open Market | 01-Jan-2011 | $262M | Completed | Profitable | ||
| 8. IPO | 12-Mar-2010 | $81M | $262M | Completed | Profitable |
AVEO Oncology Comparisons
Industry
Financing
Details
AVEO Oncology Competitors (44)
One of AVEO Oncology’s 44 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
AVEO Oncology Patents
AVEO Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024352029-A1 | Methods of reducing weight loss using anti-gdf15 antibodies | Pending | 27-Sep-2023 | ||
| EP-4784617-A1 | Methods of reducing weight loss using anti-gdf15 antibodies | Pending | 27-Sep-2023 | ||
| WO-2025072516-A1 | Methods of reducing weight loss using anti-gdf15 antibodies | Inactive | 27-Sep-2023 | ||
| WO-2023136837-A1 | Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc) | Inactive | 14-Jan-2022 | ||
| AU-2021474103-A1 | Combination therapy for treatment of cancer | Pending | 18-Nov-2021 | G01N33/57557 |
AVEO Oncology Signals
AVEO Oncology Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Biogen | Corporation | Minority | ||
| FBR & Company | Investment Bank | Minority | ||
| Flagship Pioneering | Venture Capital | Minority | ||
| GE Capital | Lender/Debt Provider | Minority |
AVEO Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
AVEO Oncology FAQs
-
When was AVEO Oncology founded?
AVEO Oncology was founded in 2001.
-
Where is AVEO Oncology headquartered?
AVEO Oncology is headquartered in Boston, MA.
-
What is the size of AVEO Oncology?
AVEO Oncology has 115 total employees.
-
What industry is AVEO Oncology in?
AVEO Oncology’s primary industry is Pharmaceuticals.
-
Is AVEO Oncology a private or public company?
AVEO Oncology is a Private company.
-
What is the current valuation of AVEO Oncology?
The current valuation of AVEO Oncology is .
-
What is AVEO Oncology’s current revenue?
The current revenue for AVEO Oncology is .
-
How much funding has AVEO Oncology raised over time?
AVEO Oncology has raised $306M.
-
Who are AVEO Oncology’s investors?
Bessemer Venture Partners, Biogen, FBR & Company, Flagship Pioneering, and GE Capital are 5 of 19 investors who have invested in AVEO Oncology.
-
Who are AVEO Oncology’s competitors?
Alnylam Pharmaceuticals, Incyte, Agenus, Merck & Co., and Amgen are some of the 44 competitors of AVEO Oncology.
-
When was AVEO Oncology acquired?
AVEO Oncology was acquired on 19-Jan-2023.
-
Who acquired AVEO Oncology?
AVEO Oncology was acquired by LG Chem.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process